



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_48076
Title of the Manuscript:	QSAR and docking study of isatin analogues As cytotoxic agent
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments		
<u>Minor</u> REVISION comments	The authors have given a reasonable QSAR and docking study on isatin analogues. There are a number of typographical and minor issues which need to be addressed before this work is published. I have highlighted these in the attached manuscript. In addition the authors will need to cross check the formatting of the references which to me are inconsistent. Finally the interactions involved at the docking sites with the relevant peptides, needs to be explained.	It was done and highlighted in the manuscript. The format of all references was check. The interaction of docking site completely explained in the manuscript and highlighted.
<u>Optional/General</u> comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	